HRs for outcomes with aspirin treatment compared with no aspirin treatment at Cox regression, in 18 646 patients with type 2 diabetes followed for 4 years
| Patients N | Events N (%) | Events/1000 person-years | HR* (95% CI) | p Value | |
|---|---|---|---|---|---|
| Non-fatal/fatal CVD | 18646 | 1003 (5.4) | 15.3 | 1.08 (0.93 to 1.24) | 0.3 |
| Fatal CVD | 18646 | 205 (1.1) | 3.1 | 0.84 (0.61 to 1.14) | 0.3 |
| Non-fatal/fatal CHD | 18646 | 698 (3.7) | 10.6 | 1.19 (1.01 to 1.41) | 0.041 |
| Fatal CHD | 18646 | 176 (0.9) | 2.6 | 0.78 (0.56 to 1.10) | 0.2 |
| Non-fatal/fatal stroke | 18646 | 338 (1.8) | 5.1 | 0.91 (0.71 to 1.16) | 0.5 |
| Fatal stroke | 18646 | 33 (0.2) | 0.5 | 1.24 (0.60 to 2.57) | 0.3 |
| Total mortality | 18646 | 655 (3.5) | 9.8 | 0.88 (0.74 to 1.06) | 0.2 |
*Adjusted by stratification with deciles of a propensity score including the covariates age, sex, diabetes duration, type of hypoglycaemic treatment, HbA1c, smoking, BMI, systolic blood pressure, ratio total-to-HDL cholesterol, albuminuria >20 µg/min, antihypertensive drugs, statins, other lipid lowering drugs, oestrogen, multidose dispensation and previous hospitalisation. Sex and HbA1c were also added as covariates.
BMI, body mass index; CHD, coronary heart disease; CVD, cardiovascular disease; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein.